[schoonder]

At ESMO late September, Roche will also release data from a two armed phaseII trial of T-DM1 vs Trastuzumab/Docetaxel, results of an evaluation which they're very excited about. The now ongoing international phaseIII trial Marianne, follow-up of this completed phaseII, was given a third arm consisting of T-DM1 and Pertuzumab.
Hopefully results from this combination show that Pertuzumab is synergistic in this setting and thus help further improve on standard of care as a first-line treatment in patients with metastatic breast cancer